Mometasone/formoterol


Mometasone/formoterol
Mometasone/formoterol
Combination of
mometasone corticosteroid
formoterol long-acting beta-adrenoceptor agonist
Clinical data
Trade names Zenhale, Dulera
AHFS/Drugs.com http://www.drugs.com/dulera.html
Licence data US Daily Med:link
Pregnancy cat. C(US)
Legal status -only (CA) -only (US)
Routes Oral Inhalation
Identifiers
ATC code  ?
 YesY(what is this?)  (verify)


Mometasone/formoterol is a combination inhaler containing both an inhaled corticosteroid and long acting bronchodilator. It is indicated for the maintenance treatment of asthma in adults and children 12 years of age and older whose asthma is not well controlled on low- or medium-dose corticosteroids, or whose disease clearly warrants combination therapy. It is not approved for the treatment of acute bronchospasm.[1] To relieve acute symptoms, a rapid-onset short-duration inhaled bronchodilator (such as salbutamol) should be available to the patient for use.[2]

Zenhale/Dulera consists of two medications supplied in a single inhaler:

The safety and efficacy of this medication in children less than 12 years of age has not been established.[2]

It is marketed by Merck & Co. in Canada as Zenhale[2] and in the United States as Dulera[1] and is supplied as a metered-dose inhaler.[1][2]

Contents

Warnings and Precautions

Long-acting beta-adrenoceptor agonists (LABAs) are subject to a black box warning against the possibility of an increased risk of asthma-related death.[2] Formoterol belongs to the LABA class of drugs. As there does not exist at the time of the monograph's publication adequate research to determine whether the rate of asthma-related death is increased with formoterol, it is therefore recommended by the FDA that LABAs only be used for patients not adequately controlled on other asthma controlling medications or whose disease severity clearly warrants initiation of dual therapy.[3]

Side effects

The most commonly reported side effects were: oral thrush, nausea, headache, and pain in the pharynx and/or larynx. More rarely reported side effects (occurring in <1% of patients during the clinical trial) include: tachycardia, palpitations, dry mouth, allergic reaction (bronchospasm, dermatitis, hives), pharyngitis, muscle spasms, tremor, dizziness, insomnia, nervousness, and hypertension. Patients experiencing an allergic reaction or increase in difficulty breathing while using this medication should immediately discontinue its use and contact their physician.[4]

How Supplied and Dosage

Zenhale/Dulera is available in a pressurized MDI (pMDI) in three strengths (in micrograms of mometasone/micrograms of formoterol): 50/5, 100/5, and 200/5. The following is the manufacturer's recommended dose based on prior asthma therapy:[2]

  • Inhaled low-dose corticosteroids: 50/5 2 inhalations twice daily to a maximum of 200/20 micrograms daily
  • Inhaled medium-dose corticosteroids: 100/5 2 inhalations twice daily to a maximum of 400/20 micrograms daily
  • Inhaled high dose corticosteroids: 200/5 2 inhalations twice daily to a maximum of 800/20 micrograms daily

Market

Zenhale was approved in Canada in early 2011.[5] Dulera was approved by the Food and Drug Administration (FDA) in the United States in June 2010.[6] Zenhale's marketing application was voluntarily withdrawn from the EU due to the manufacturer's inability to provide additional information in the necessary timeframe.[7]

References


Wikimedia Foundation. 2010.

Look at other dictionaries:

  • Formoterol — Systematic (IUPAC) name rac (R,R) N [2 hydroxy 5 [1 hydroxy 2 [1 (4 methoxyphenyl) propan 2 ylamino]ethyl] phenyl]formamide Clinical data …   Wikipedia

  • Budesonide — Systematic (IUPAC) name 16,17 (butylidenebis(oxy)) 11,21 dihydroxy , (11 β,16 α) pregna 1,4 diene 3,20 dione Clinical data Trade names …   Wikipedia

  • Triamcinolone — Systematic (IUPAC) name (11β,16α) 9 fluoro 11,16,17,21 tetrahydroxypregna 1,4 diene 3,20 dione Clinical data Trade names …   Wikipedia

  • Beclometasone dipropionate — Systematic (IUPAC) name (8S,9R,10S,11S,13S,14S,16S,17R) 9 chloro 11 hydroxy 10,13,16 trimethyl 3 oxo 17 [2 (propionyloxy)acetyl] 6,7,8,9,10,11,12,13,14,15,16,17 dodecahydro 3H cyclo …   Wikipedia

  • Flunisolide — Systematic (IUPAC) name (1S,2S,4R,8S,9S,11S,12S,13R,19S) 19 fluoro 11 hydroxy 8 (2 hydroxyacetyl) 6,6,9,13 tetramethyl 5,7 dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa 14,17 dien 16 one …   Wikipedia

  • Ciclesonide — Systematic (IUPAC) name 2 [(1S, 2S, 4R, 8S, 9S,11S, 12S, 13R) 6 cyclohexyl 11 hydroxy 9, 13 dimethyl 16 oxo 5, 7 dioxapentacyclo [10.8.0.02,9.04, 8.013,18] icosa 14, 17 dien 8 yl] 2 oxoethyl 2 …   Wikipedia

  • Fluticasone propionate — Systematic (IUPAC) name S (fluoromethyl) 6α,9 difluoro 11β, 17 dihydroxy 16α methyl 3 oxoandrosta 1, 4 diene 17β carbothioate, 17 propanoate Clinical data …   Wikipedia

  • Indacaterol — Systematic (IUPAC) name (R) 5 [2 [(5,6 Diethyl 2,3 dihydro 1H inden 2 yl)amino] 1 hydroxyethyl] 8 hydroxyquinolin 2(1H) one …   Wikipedia

  • Cromoglicic acid — Systematic (IUPAC) name 5,5′ (2 hydroxypropane 1,3 diyl)bis(oxy)bis(4 oxo 4H chromene 2 carboxylic acid) Clinical data AHFS/ …   Wikipedia

  • Betamethasone — Systematic (IUPAC) name (8S,9R,10S,11S,13 …   Wikipedia


Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.